Skip to main content
Clinical Trials/JPRN-jRCTs052220080
JPRN-jRCTs052220080
Recruiting
Phase 1

Safety evaluation and therapeutic effects of exercise therapy and knee hyperthermia using reentrant cavity resonance warmer for early knee osteoarthritis

Ryu Kazuteru0 sites30 target enrollmentAugust 25, 2022
Conditionsosteoarthritis

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
osteoarthritis
Sponsor
Ryu Kazuteru
Enrollment
30
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 25, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Ryu Kazuteru

Eligibility Criteria

Inclusion Criteria

  • 1\) Patients participating in exercise therapy for locomotive syndrome at Kanai Hospital
  • 2\) Patients with early stage osteoarthritis of the knee (radiographs: Kellgren\-Lawrence classification grade 1\-2\)
  • 3\) Gender: male and female
  • 4\) Age: between 40 and 80 years old
  • 5\) BMI: 30 or less
  • 6\) Patients who can provide written consent for free participation in the study

Exclusion Criteria

  • 1\) Patients who cannot walk without the assistance of others
  • 2\) Persons whose cognitive ability is recognized as declining (persons scoring 23 or below on the Hasegawa Dementia Scale are excluded).
  • 3\) Those residing in a special nursing home for the elderly, long\-term care health facility for the elderly, or long\-term care medical facility (convalescent beds)
  • 4\) Patients with a history of hospitalization within 1 month of the date of consent
  • 5\) Those with a history of trauma or surgery to the lower limb or spine within 3 months of the date of consent
  • 6\) Has a pacemaker inserted
  • 7\) Pregnant women
  • 8\) Patients who are unable to perform MRI examinations (metal in the body, claustrophobia, etc.)
  • 9\) Patients who are unable to hold the position for 20 minutes
  • 10\) Persons who have a conflict of interest with the principal investigator or co\-investigator of this study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Determining the Safety and Benefits of Exercising Patients with a Tracheostomy and a Speaking ValveRespiratory DysfunctionRespiratory - Other respiratory disorders / diseases
ACTRN12619000148178Physiotherapy Department - The Prince Charles Hospital20
Withdrawn
Not Applicable
The safety, feasibility and effect of an exercise training program in palliative care on quality of life for patients with cancer: a randomized controlled trial.cancerNeoplasm10027655
NL-OMON46195Haaglanden Medisch Centrum255
Recruiting
Phase 1
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes MellitusType 1 diabetes mellitusDiabetes Mellitus, Type 1Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases
RPCEC00000225Center of Molecular Immunology (CIM)40
Active, not recruiting
Phase 1
Preliminary effect and safety of physiotherapy with strength training and protein-dense nutritional supplement in combination with anabolic steroids in cross-continuum rehabilitation of patients with hip fracture.Area of investigation is recovery of muscle strength and function following hip fracture surgery.MedDRA version: 20.1Level: LLTClassification code 10017287Term: Fractured hipSystem Organ Class: 100000004863MedDRA version: 20.1Level: LLTClassification code 10017299Term: Fractured neck of femurSystem Organ Class: 100000004863MedDRA version: 20.1Level: LLTClassification code 10034736Term: Pertrochanteric fracture of femur, closedSystem Organ Class: 100000004863MedDRA version: 20.1Level: LLTClassification code 10053653Term: Femur fracture subtrochantericSystem Organ Class: 100000004863Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2017-001543-13-DKMorten Tange Kristensen/Hvidovre Hospital48
Not yet recruiting
Phase 1
euroEPO – Type 2 Spinocerebellar Ataxia Phase I-IIType 2 Spinocerebellar Ataxia
RPCEC00000187Center of Molecular Immunology (CIM), CIMAB34